Pivekimab, known as IBAT®, is the novel recombinant monoclonal antibody developed with directly interact with or inhibit interleukin-6, a critical inflammatory mediator involved in various pathogenic responses underlying inflammatory illnesses. The therapeutic molecule has been produced using recombinant genetic material techniques, facilitating t

Basiliximab, previously identified as CHI 621 and possessing the chemical identifier 179045-86-4, represents a therapeutic agent utilized primarily in suppressing acute repudiation following organ transplantation . This engineered immunoglobulin specifically interacts with the interleukin-2 (IL-2) receptor , effectively inhibiting IL-2 communicatio